Clinical Effect Analysis of Octreotide in The Treatment of Neonatal Necrotizing Enterocolitis

Objective: To explore the clinical effect of octreotide in the treatment of neonatal necrotizing enterocolitis. Methods: 50 cases of children with necrotizing enterocolitis treated in our hospitalfrom January 2023 to October 2024 were selected and divided into groups by randomization. The positive side was the reference group treated with conventional drugs (n = 25), and the negative side was the experimental group treated with conventional drugs + octreotide (n = 25). The therapeutic effect, nutritional status and intestinal colony of the two groups were observed and compared. Results: The total effective rate of the two groups was significantly improved, and the total effective rate of the experimental group was significantly higher than that of the reference group (P < 0.05); After treatment, the nutritional status indexes of the two groups were significantly improved compared with those before treatment, and the albumin (ALB) and serum prealbumin (PA) of the experimental group were significantly higher than those of the reference group (P < 0.05); After treatment, compared the two groups of patients, the indicators of intestinal flora had significant changes compared with those before treatment, in which the level of HMGB1 in the experimental group was significantly lower than that in the reference group, while hBD2 and AI-2 in the experimental group were significantly higher than that in the reference group (P < 0.05). Conclusion: Octreotide in the treatment of neonatal necrotizing enterocolitis can effectively improve the therapeutic effect of the disease, further improve the nutritional status of patients, and promote the significant improvement of intestinal colonies.